The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Update of the guidelines for lupus anticoagulant detection
Open accessAbstract
One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspects discussed in this official communication. A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing. Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT. Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, persistently positive LAC and/or moderate/high Sapporo criteria aPL Abs (aCL IgG or IGM, or anti-b2GPI IgG or IgM) (10) were associated with HCQ use, OR 0.24 (0.06, 0.94), p=0.04”
From Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last update of the guidelines for LA detection by the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009 12 has proven useful in achieving greater uniformity in performance and interpretation of LA testing.”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, on other points, including testing in patients on anticoagulation, cutoff values, and calculation and interpretation of results, there was uncertainty or lack of agreement.12,15”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For samples from patients with no other causes of clotting time prolongation and LA assay confirmatory test results within reference intervals, the increasingly popular paradigm of integrated testing is sufficient to detect the presence of LA without performing the mixing test at all.6, 7, 8, 9, 26, 27, 28, 31, 33, 34”
From Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixing test is mainly to discriminate between the presence of an inhibitor and coagulation factor deficiencies such as those occurring in patients on conventional oral anticoagulants/vitamin K antagonists (VKA).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines recommend mixing tests are interpreted with either a mixing test specific cut‐off (MTC) or the index of circulating anticoagulant (ICA).”
The cited source says what the claim attributes to it.
In the citing paper
“There is no single test to detect all LA1, 6, 7, 8 and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA‐sensitive activated partial thromboplastin time (APTT).6, 7, 8”
The cited source says what the claim attributes to it.
In the citing paper
“LA positivity was determined following the Scientific and Standardization Committee (SSC)/International Society on Thrombosis and Hemostasis (ISTH) recommendations at the time of testing.11,13”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The lupus anticoagulant assay (LA) followed international guidelines for the performance of this functional assay (54).”
From Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA (2019) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“According to ISTH/SSC (1) and CLSI (2) guidelines LAC identification should include three steps: screening for prolongation in a phospholipid-sensitive test, mixing with normal plasma to identify failure to correct and confirmation through result shortening in a phospholipid-rich test, (though in slightly different priority with CLSI).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Results were expressed as normalized ratios and interpreted according to in-house calculated cut-off values calculated with the 99th percentile (1).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Testing patients during VKA or other anticoagulant therapy for LAC remains a contentious issue and has been discouraged by official guidelines (1, 2) because of interpretational problems affecting the mixing test (8-10).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Because there is no single assay sensitive to all LA antibodies, at least 2 coagulation tests based on different assay principles are recommended for LA detection [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Various interpretation indices, including percentage of correction (%Correct), screen-to-confirm ratio (SCR), and normalized SCR (NSCR), are suggested to determine the presence of LA in these phospholipid-dependent assays [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Laboratory tests for LA detection comprise complex and multistep coagulation testing procedures, including screening, confirmatory, and mixing tests [[11], [12], [13]], and heterogeneity in these is an important cause of interlaboratory variation.”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The diluted Russell’s viper venom time (dRVVT) assay is the first recommended test for detecting LA due to its high sensitivity and specificity [14], while the LA-sensitive activated partial thromboplastin time (aPTT) assay can be used as a secondary test [[11], [12], [13], [14]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“LAC was determined using the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnières-sur-Seine, France) according to ISTH guidelines 1 applying dilute Russell ' s viper venomtime (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, Diagnostica Stago, Asnières-sur-”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“This study supports the dRVVT as the preferred assay to detect LAC. 1”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and LAC was performed according to the ISTH guidelines. 1,34”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“LA was determined using two clotting assays as recommended by the 2009 International Society on Thrombosis and Haemostasis (ISTH) guidelines, 21 which were applicable at the time of the study: APTT by Diagnostica Stago and dRVVT by HYPHEN BioMed. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“However, the samples were analyzed before the publication of these new guidelines and therefore interpreted according to the guidelines that were applicable at this time. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The majority of survey participants indicated that the number should be at least 40, which seems reasonable to guarantee an overall normal clotting factor activity. 12”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Self-citationDetection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity
Rosner, E., Pauzner, R., Lusky, A., Modan, M., & Many, A. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651083 · Cited by 188
Galli, M., Finazzi, G., Bevers, E. M., & Barbui, T. (1995) · Blood · doi:10.1182/blood.v86.2.617.bloodjournal862617 · Cited by 146
Self-citationA Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132
The Textarin/Ecarin Ratio: A Confirmatory Test for Lupus Anticoagulants
Triplett, D. A., Stocker, K. F., Unger, G. A., & Barna, L. K. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649701 · Cited by 110
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Cited by
Sorted by citations
Items 701–800 of 1,001
Mayer-Pickel, K. I., Stern, C., Cervar-Zivkovic, M., Schöll, W., & Moertl, M. G. (2020) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2020.103101 · Cited by 8
Cabrera-Marante, Ó., Pleguezuelo, D. E., Garcinuño, S., Naranjo, L., Díaz‐Simón, R., Gil‐Etayo, F. J., Zafra, D., Lozano-Morillo, F., Morillas, L., Abad, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1636171 · Cited by 7
Jourdi, G., Flaujac, C., de Maistre, E., Gendron, N., Eschwège, V., Mauge, L., & on behalf of the French Society on Thrombosis Haemostasis (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2695-2674 · Cited by 7
Changes of platelet count throughout pregnancy in women with antiphospholipid syndrome
Mayer-Pickel, K. I., Stern, C., Eberhard, K., Lang, U., & Cervar-Zivkovic, M. (2019) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2019.102612 · Cited by 7
Levine, A. B., & Lockshin, M. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0673-4_6 · Cited by 7
Ibrahim, A. A., Shadi, H. W. E., Elamin, A. A. Y., & Draz, H. E. (2023) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-023-00175-z · Cited by 7
Li, S., Zhao, J., Bai, Y., Meng, J., Wang, Q., Tian, X., Li, M., Zeng, X., & Hu, C. (2023) · Rheumatology · doi:10.1093/rheumatology/kead303 · Cited by 8
Roselli, D., Bonifacio, M. A., Barbuti, G., Rossiello, M. R., Ranieri, P., & Mariggiò, M. A. (2023) · Diagnostics · doi:10.3390/diagnostics13152507 · Cited by 7
Zhou, Y., Hu, C., Qi, W., Long, Y., Huang, C. L., Wang, Q., Tian, X., Zhao, J., Li, M., & Zeng, X. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000924 · Cited by 7
Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic stroke
Geng, L., Pan, K., Xu, Y., Zhang, B., Wang, J., Xue, Q., Zhang, S., Su, H., & Zhang, B. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107885 · Cited by 7
Laer, M. V., Penaloza, A., Stockman, W., Meert, P., Lambert, C., & Hermans, C. R. J. R. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000799 · Cited by 7
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?
Franchini, M., Schiavulli, M., & Liumbruno, G. M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1892483 · Cited by 7
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies
Radin, M., Barinotti, A., Foddai, S. G., Cecchi, I., Rubini, E., Roccatello, D., Menegatti, E., & Sciascia, S. (2021) · Immunologic Research · doi:10.1007/s12026-021-09208-1 · Cited by 7
dos Santos, A. P. R., Vaz, C. D. O., Hounkpe, B. W., Jacintho, B. C., Oliveira, J. D., Mesquita, G. L. T. V., dos Santos, I. P., Annichino‐Bizzacchi, J. M., Appenzeller, S., Mazetto, B. D. M., et al. (2022) · Lupus · doi:10.1177/09612033221101731 · Cited by 7
Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome
Riva, N., & Gatt, A. (2019) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10314116 · Cited by 7
An Overview of Laboratory Testing for Antiphospholipid Antibodies
Favaloro, E. J., & Pasalic, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3175-1_15 · Cited by 8
Hoxha, A., Perin, N., Lovisotto, M., Calligaro, A., Ross, T. D., Favarò, M., Tonello, M., Doria, A., & Simioni, P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103180 · Cited by 7
Lincz, L. F., Scorgie, F. E., Johnston, C. I., O’Leary, M. A., Prasad, R., Seldon, M., Favaloro, E. J., & Isbister, G. K. (2014) · Pathology · doi:10.1097/pat.0000000000000120 · Cited by 7
Mameli, A., Barcellona, D., Vannini, M. L., & Marongiu, F. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.111 · Cited by 7
Mattia, E., Ruffatti, A., Meneghel, L., Tonello, M., Faggian, D., Hoxha, A., Fedrigo, M., Punzi, L., & Plebani, M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.012 · Cited by 7
Favaloro, E. J. (2011) · Pathology · doi:10.1097/pat.0b013e3283468c70 · Cited by 7
Breen, K. A., Kilpatrick, D. C., Świerzko, A. S., Cedzyński, M., & Hunt, B. J. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000060 · Cited by 7
Mohammadi, M. M., & Bozorgi, S. (2019) · Journal of Laboratory Medicine · doi:10.1515/labmed-2018-0084 · Cited by 7
Carubbi, F., Alunno, A., Cipriani, P., Bistoni, O., Scipioni, R., Liakouli, V., Ruscitti, P., Berardicurti, O., Bartolomeo, S. D., Gerli, R., et al. (2018) · Current Rheumatology Reviews · doi:10.2174/1573397114666180320113603 · Cited by 7
Khodashahi, M., REZAIEYAZDI, Z., & SAHEBARI, M. (2020) · Archives of Rheumatology · doi:10.5606/archrheumatol.2020.7375 · Cited by 8
Akikusa, J., & Choo, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00010-7 · Cited by 7
Velasco‐Rodríguez, D., Laso, R. V., García‐Raso, A., Mahíllo, I., Guzmán-López, K., Martín‐Herrero, S., Barral, E. J., Vegas-Sánchez, M. C., Martínez-Becerra, M. J., de la Plaza, R., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.025 · Cited by 7
Plasín-Rodríguez, M. A., Patrício, P., Monteagudo, J., García‐Criado, Á., Cervera, R., Reverter, J. C., Espinosa, G., & Tàssies, D. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02295-1 · Cited by 7
Olivieri, G., Ceccarelli, F., Natalucci, F., Pirone, C., Orefice, V., Pacucci, V. A., Garufi, C., Truglia, S., Spinelli, F. R., Alessandri, C., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105246 · Cited by 7
The Presence of Antiphospholipid Antibodies in Healthy Bernese Mountain Dogs
Nielsen, L. N., Wiinberg, B., Kjelgaard-Hansen, M. J., & Kristensen, A. T. (2011) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2011.00823.x · Cited by 7
Laboratory Diagnosis of Antiphospholipid Syndrome
An, G., Lim, H., & Han, J. (2017) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.17002 · Cited by 9
Variants in chondroitin sulfate metabolism genes in thrombotic storm
Nuytemans, K., Ortel, T. L., Gomez, L., Hofmann, N. K., Alves, N., Dueker, N., Beecham, A. H., Whitehead, P. L., Hahn, S. E., Kitchens, C. S., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.11.016 · Cited by 7
Self-citationKhamashta, M. A., & Amigo, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00139-x · Cited by 8
Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
Spencer, A., Pearce, M. I., & Ames, P. R. J. (2011) · Thrombosis Journal · doi:10.1186/1477-9560-9-16 · Cited by 7
Breen, K. A. (2017) · Wiley eBooks · doi:10.1002/9781119095606.ch8 · Cited by 7
Khellaf, M., Meisner, P. D., Sarno, M., Zaremba, P., Jędrzejczyk, A., & Scowcroft, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084563 · Cited by 6
Assessment of 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort
Estefanía, R. C., Sánchez, R. G., Casuso, M. A., García, J. A. F., Ruiz, R. G., Álvarez, I. G., Barquín, H. C., Madrid, M. O., López, M. H., Rodríguez, L. G. G., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0508 · Cited by 6
Moe, S. R., Haukeland, H., Brunborg, C., Botea, A., Damjanic, N., Wivestad, G. Å., Øvreås, H. K., Bøe, T. B., Orre, A., Garen, T., et al. (2025) · RMD Open · doi:10.1136/rmdopen-2025-005795 · Cited by 6
Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests
Bertolaccini, M. L., Amengual, O., Artim-Esen, B., Atsumi, T., de Groot, P. G., de Laat, B., Devreese, K. M. J., Giles, I., Meroni, P. L., Borghi, M. O., et al. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_8 · Cited by 6
Self-citationLimitations of a calibrated, quantitative APC‐R assay under routine conditions
Jilma‐Stohlawetz, P., Lysy, K., Sunder‐Plaßmann, R., Belik, S., Jilma, B., Pabinger, I., & Quehenberger, P. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13378 · Cited by 6
Hasan, H., Surjancev, I., Arnason, J. A., Garg, S., & Rose, W. N. (2023) · Case Reports in Rheumatology · doi:10.1155/2023/3226278 · Cited by 6
Chikasawa, Y., Amano, K., Shinozawa, K., Bingo, M., Miyashita, R., Yamaguchi, T., Mitsuhashi, A., Inaba, H., Hagiwara, T., & Kinai, E. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03659-y · Cited by 6
Zen, M., Tonello, M., Favarò, M., Ross, T. D., Calligaro, A., Giollo, A., Vesentini, F., Gennaio, I. A., Arru, F., Ruffatti, A., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead517 · Cited by 6
Shobha, V., Rajasekhar, L., Manuel, S., Nayana, V., Kavadichanda, C. G., Kounassegarane, D., Mathew, A. J., Gupta, R., Rathi, M., Ghosh, P., et al. (2023) · Rheumatology International · doi:10.1007/s00296-023-05511-2 · Cited by 6
Acquired Bleeding Disorders in Children
Kumar, R., & Steele, M. (2013) · KARGER eBooks · doi:10.1159/000346955 · Cited by 6
Li, R., Daguzan, M., Vandermijnsbrugge, F., Gyling, M., & Cantinieaux, B. (2014) · Acta Clinica Belgica · doi:10.1179/2295333714y.0000000060 · Cited by 6
Laboratory Investigation of Thrombophilia / LABORATORIJSKO ISPITIVANJE TROMBOFILIJA
Margetić, S. (2013) · Journal of Medical Biochemistry · doi:10.2478/jomb-2013-0041 · Cited by 6
The association of serum antiphospholipid antibodies and dilute Russell's viper venom times
Froom, P., Saffuri-Elias, E., Rozenberg, O., & Barak, M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201830 · Cited by 6
Gardiner, C., Kohama, K., Patel, I., Lane, P. J., Dwyer, S., Machin, S. J., & Mackie, I. J. (2017) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12691 · Cited by 6
Cansu, D. Ü., Teke, H. Ü., Musmul, A., & Korkmaz, C. (2017) · Rheumatology International · doi:10.1007/s00296-017-3872-5 · Cited by 6
Stojanovich, L., Djoković, A., Stanisavljević, N., & Zdravkovic, M. D. (2018) · Lupus · doi:10.1177/0961203317751065 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Lackner, K. J., & Müller‐Calleja, N. (2018) · Hämostaseologie · doi:10.1055/s-0038-1675355 · Cited by 6
Biochemistry, Lupus Anticoagulant
Rasool, Z. S., & Tiwari, V. (2019) · StatPearls · Cited by 6
Syndrome des antiphospholipides « séronégatif » : mythe ou réalité ?
Salle, V. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.02.005 · Cited by 6
Elkhateb, I. T., Mousa, A., Mohamed, R. M. E., & Soliman, Y. S. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-237781 · Cited by 6
Does incomplete obstetric antiphospholipid syndrome really exist?
Alijotas‐Reig, J. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2020.12.023 · Cited by 6
Menet, J., Agrinier, N., Dufrost, V., Conart, J., Wahl, D. G., Angioï-Duprez, K., & Zuily, S. (2021) · Lupus · doi:10.1177/09612033211033988 · Cited by 6
Barilaro, G., Rocca, C. D., Esteves, A., Cervera, R., & Espinosa, G. (2022) · Rheumatology · doi:10.1093/rheumatology/keac619 · Cited by 6
Na, Y. S., Jang, S., Hong, S., Oh, Y., Lee, S., & Lee, J. S. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0045 · Cited by 6
Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies
Cruz, A. C. L., Colella, M. P., Paula, E. V. D., Annichinno‐Bizzachi, J., & Orsi, F. A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.08.013 · Cited by 6
Barilaro, G., Espinosa, G., & Cervera, R. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.03.012 · Cited by 7
Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations
Donadini, M. P., & Crowther, M. A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.05.005 · Cited by 6
de Mesquita, H. L., de Carvalho, G. R., Aarestrup, F. M., Corrêa, J. O. D. A., & de Azevedo, M. R. A. (2013) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042013000500006 · Cited by 6
Investigation of a Thrombotic Tendency
Laffan, M., & Manning, R. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6696-2.00019-9 · Cited by 6
Mediwake, H., Robertson, J. D., Beggs, J., & Mason, J. A. (2018) · TH Open · doi:10.1055/s-0038-1624567 · Cited by 6
Lupus Anticoagulants, Antiphospholipid Antibodies, and Antiphospholipid Syndrome
Nichols, W. L., Kottke‐Marchant, K., Ledford-Kraemer, M., Homburger, H. A., & Cardel, L. K. (2012) · Wiley eBooks · doi:10.1002/9781444398595.ch39 · Cited by 6
Lupus anticoagulant test persistence over time and its associations with future thrombotic events
Colling, M. E., Ay, C., Kraemmer, D., Koder, S., Quehenberger, P., Pabinger, I., Posch, F., & Gebhart, J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006011 · Cited by 5
“(26-43), respectively, and a 10-year mortality of 14% (9-22) (Supplementary Figure 2).”
BackgroundAnalytical dilemmas in lupus anticoagulant detection
Moore, G. W. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00104 · Cited by 5
Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome
Efthymiou, M., Bertolaccini, M. L., & Cohen, H. (2024) · Rheumatology · doi:10.1093/rheumatology/kead623 · Cited by 5
Anticoagulation Failure in Stroke: Causes, Risk Factors, and Treatment
Choi, Y.-B., & Kim, J. S. (2025) · Journal of Stroke · doi:10.5853/jos.2025.00206 · Cited by 6
Yelnik, C., Bauters, A., Labreuche, J., Desvages, M., Launay, D., HACHULLA, E., Dubucquoi, S., Lancel, S., Frimat, M., & Lambert, M. (2025) · RMD Open · doi:10.1136/rmdopen-2025-005489 · Cited by 5
Shimomura, D., Kumano, O., Ueda, K., Kitano, K., Arai, N., Shimada, M., & Kamioka, M. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14289 · Cited by 5
Žigon, P., Boštic, N., Ambrožič, A., Rotar, Ž., Blokar, E., Ogrič, M., & Čučnik, S. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0570 · Cited by 5
Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies
Swadźba, J., Sydor, W., Kołodziejczyk, J., & Musiał, J. (2014) · Lupus · doi:10.1177/0961203314520841 · Cited by 5
Ahuja, A., Tyagi, S., Pati, H. P., Saxena, R., Somasundaram, V., Manivannan, P., Tripathi, P., & Chandra, D. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-018-01072-8 · Cited by 5
Sciascia, S., Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Vaccarino, A., Rossi, D., & Roccatello, D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.621590 · Cited by 5
Álvarez, D., Rúa, C., Velásquez, M., Cataño, J. U., Escudero, C., & J, Á. P. C. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102905 · Cited by 5
Lupus anticoagulant laboratory diagnosis by applying the 2020 ISTH-SSC guidelines
Talon, L., Fourneyron, V., Senectaire, S., Tardieu, M., Tillier, M., Trapani, A., Trayaud, A., Vaissade, A., Sapin, A.-F. S., Lebreton, A., et al. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.02.009 · Cited by 6
Real‐world experience of direct oral anticoagulant use in a single pediatric center
Valenti, G. G., Sabo, C. S., Hyde, M., & Rajpurkar, M. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.30926 · Cited by 5
IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients
Mellor‐Pita, S., Tutor‐Ureta, P., Velasco, P., Plaza, A., Diego‐Yagüe, I., Vázquez‐Comendador, J., Vionnet, A. P., Campo, P. D., Moreno‐Torres, V., Vargas, J. A., et al. (2024) · Viruses · doi:10.3390/v16071071 · Cited by 5
Darnige, L., de Latour, R. P., Zemori, L., Socié, G., Fischer, A., Helley, D., & on behalf of the French Society of Haematology (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08665.x · Cited by 5
Quality in Hemostasis and Thrombosis, Part II
Plebani, M., Favaloro, E. J., & Lippi, G. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1334446 · Cited by 5
Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies
Sugiura‐Ogasawara, M., Atsumi, T., Yamada, H., Kitaori, T., Ozaki, Y., Katano, K., & Murashima, A. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1023978 · Cited by 5
Challenging hemostasis scenarios in pediatric patients – two case studies
Moser, K. A., & Puetz, J. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12355 · Cited by 5
Laboratory Approach to Thrombotic Risk
Marlar, R. A., Fink, L. M., & Miller, J. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00041-5 · Cited by 5
Nojima, J., Motoki, Y., Hara, K., Sakata, T., & Ichihara, K. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000599 · Cited by 5
Annem, C., & Furie, R. A. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000564 · Cited by 5
Campello, E., Radu, C., Tonello, M., Kuzenko, A., Bulato, C., Hoxha, A., Mattia, E., Spiezia, L., Ruffatti, A., & Simioni, P. (2018) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2017.1372518 · Cited by 5
Kwon, H.-M., Jung, K., Moon, Y., Jung, H., Park, Y.-S., Jun, I., Song, J., & Hwang, G. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.02.034 · Cited by 5
Rand, J. H., & Taatjes, D. J. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1709-2 · Cited by 5
Self-citationPathogenesis of Antiphospholipid Antibody Syndrome
Giles, I., Cohen, H., & Ioannou, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00024-4 · Cited by 5
Yang, F., Tang, N., Zhang, H., Li, G., Zhang, H., & Zhang, C. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-3402477 · Cited by 5
Laboratory Approaches to Test the Function of Antiphospholipid Antibodies
Szabó, G., Antal‐Szalmás, P., Kerényi, A., Pénzes, K., Bécsi, B., & Kappelmayer, J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1730357 · Cited by 5
Kempers, E. K., Dalm, V. A. S. H., van Rijn, M. J. E., Mulders, A. G. M. G. J., Leebeek, F. W. G., de Maat, M. P. M., & Jansen, A. J. G. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab093 · Cited by 5
A retrospective review of antiphospholipid syndrome from a South Asian country
Mushtaq, M. Z., Ali, S. A., Sattar, Z., Mahmood, S. B. Z., Amber, T., & Riaz, M. (2021) · Archives of Rheumatology · doi:10.46497/archrheumatol.2022.8979 · Cited by 5
Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity
Sun, F., Zhao, L., Wang, H., Zhang, D., Chen, J., Wang, X., Li, T., & Ye, S. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000657 · Cited by 5
Bradáčová, P., Slavík, L., Skoumalová, A., Úlehlová, J., Kriegová, E., Manukyan, G. P., Friedecký, D., Piskláková, B., Ullrychová, J., Procházková, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168973 · Cited by 5
Masson, C., Nguyen, T. T., Dufrost, V., AUDRAIN, M. A. P., Hémont, C., Agard, C., Artifoni, M., Connault, J., Fouassier, M., Hamidou, M. A., et al. (2022) · Lupus · doi:10.1177/09612033221130975 · Cited by 5
Daughety, M. M., Erkan, D., Lockshin, M. D., & Ortel, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00061-7 · Cited by 5
Self-citation
Metadata
- Authors
- PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G.
- Affiliations
- University of Padua (IT)
- University of Milan (IT)
- University Hospital of Geneva (CH)
- Montefiore Medical Center (US)
- Duke Medical Center (US)
- Corresponding author
- PENGO, V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1737-1740
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069797332
- Cited by
- 1,197
- References
- 21
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 53 · 2023: 55 · 2022: 65 · 2021: 89 · 2020: 99 · 2019: 101 · 2018: 88 · 2017: 82 · 2016: 80 · 2015: 75 · 2014: 81 · 2013: 69 · 2012: 82
- FWCI
- 48.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, patient selection, activated partial thromboplastin time, cut-off values, interpretation of results, diagnostic guidelines
- MeSH terms
- Anticoagulants, Blood Coagulation, Blood Specimen Collection, Female, Humans, Indicators and Reagents, Male, Partial Thromboplastin Time, Phospholipids, Pregnancy, Pregnancy Complications, Hematologic, Prothrombin Time, Specimen Handling, Vitamin K, Artifacts, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
